Work

296P Integrative discovery and preclinical validation establish RANKL, TIGIT, and CD47 triple blockade as a potent strategy for cervical cancer

Year: 2025

Type: article

Abstract: Cervical cancer (CC) remains a leading cause of cancer mortality among women worldwide, with limited benefit from current immunotherapies. Since CC is immunogenic, immunotherapy beyond PD-1/PD-L1 is urgently needed. We hypothesized that integration of molecular profiling with functional studies could identify rational combination immunotherapies, focusing on the immunoregulatory receptor activator of nuclear factor κB (RANK) axis.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2025.101495